Alzheimer's Disease Pathogenesis: Classic Versus Novel Perspectives
DOI:
https://doi.org/10.54097/k0zpn865Keywords:
Alzheimer's disease (AD), β-amyloid protein (Aβ), Tau, drug targets.Abstract
Alzheimer's disease (AD) is a neurodegenerative disease of the central nervous system characterized by progressive cognitive impairment and behavioral deficits. Its pathogenesis is complex and has not been fully elucidated to date. This review aims to systematically elaborate on the multifactorial pathogenic mechanisms of AD. Traditionally, senile plaques formed by β-amyloid (Aβ) deposition and neurofibrillary tangles caused by hyperphosphorylation of the microtubule-associated protein Tau are regarded as the core pathological features of AD. In recent years, studies have found that microglial dysfunction, gut microbiota dysbiosis, mitochondrial dysfunction, and genetic risk factors all play key roles in the occurrence and progression of AD. These mechanisms are intertwined, forming a complex network that collectively drives neuronal loss and synaptic damage. This article reviews the latest research progress on the aforementioned major mechanisms, aiming to provide a theoretical basis for in-depth understanding of the pathophysiological processes of AD. Finally, based on the understanding of the multi-mechanism network, this article prospects the multimodal therapeutic strategies targeting Aβ, Tau, and neuroinflammation in combination, which may be an important direction for the development of new AD drugs in the future.
Downloads
References
[1] The Editors of Encyclopaedia Britannica. Alzheimer disease. Encyclopedia Britannica, 2025 - 07 - 29. https://www.britannica.com/science/Alzheimer-disease.
[2] Ahmed T F, Ahmed A, Imtiaz F. History in perspective: How Alzheimer’s Disease came to be where it is? Brain Research, 2021, 1758: 147342.
[3] Kamatham P T, Shukla R, Khatri D K, et al. Pathogenesis, diagnostics, and therapeutics for Alzheimer’s disease: Breaking the memory barrier. Ageing Research Reviews, 2024, 101: 102481.
[4] World Health Organization. World failing to address dementia challenge. WHO News, 2021 - 09 - 02. https://www.who.int/news/item/02-09-2021-world-failing-to-address-dementia-challenge.
[5] Hardy J A, Higgins G A. Alzheimer's Disease: The Amyloid Cascade Hypothesis. Science, 1992, 256 (5054): 184 - 185.
[6] Zhao Shiying, Zhang Hui. Progress in the pathogenesis of Alzheimer’s disease. Hebei Medical Journal, 2025, 47 (7): 1187 - 1191.
[7] Valiukas Z, Tangalakis K, Apostolopoulos V, et al. Microglial activation states and their implications for Alzheimer’s Disease. The Journal of Prevention of Alzheimer’s Disease, 2025, 12: 100013.
[8] Singh H, Chopra C, Singh H, et al. Gut-brain axis and Alzheimer’s disease: Therapeutic interventions and strategies. Journal of Functional Foods, 2024, 112: 105915.
[9] D’Alessandro M C B, Kanaan S, Geller M, et al. Mitochondrial dysfunction in Alzheimer’s disease. Ageing Research Reviews, 2025, 107: 102713.
[10] Hroudová J, Fišar Z. Targeting mitochondrial dysfunction in Alzheimer's disease: New findings and perspectives. Progress in Neuropsychopharmacology & Biological Psychiatry, 2025, 142: 111491.
[11] Fu W-Y, Ip N Y. The role of genetic risk factors of Alzheimer’s disease in synaptic dysfunction. Seminars in Cell and Developmental Biology, 2023, 139: 3 - 12.
[12] Sa A N, Kaur A, Kumar A, et al. The genetic risk factors, molecular pathways, microRNAs, and the gut microbiome in Alzheimer’s disease. Neuroscience, 2025, 577: 217 - 227.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Academic Journal of Science and Technology

This work is licensed under a Creative Commons Attribution 4.0 International License.








